Results 91 to 100 of about 291 (113)
Some of the next articles are maybe not open access.
Endocrine Practice
Somapacitan is the first approved and currently the only long-acting growth hormone (GH) formulation in the United States for treatment of adults with growth hormone deficiency (GHD). The aim of this review was to provide a practical approach for clinicians on how to utilize somapacitan in the treatment of adults with GHD.Literature search was ...
exaly +3 more sources
Somapacitan is the first approved and currently the only long-acting growth hormone (GH) formulation in the United States for treatment of adults with growth hormone deficiency (GHD). The aim of this review was to provide a practical approach for clinicians on how to utilize somapacitan in the treatment of adults with GHD.Literature search was ...
exaly +3 more sources
Canadian Journal of Health Technologies, 2023
CADTH recommends that Sogroya should be reimbursed by public drug plans for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency [GHD]) if certain conditions are met. Sogroya should only be covered to treat children who are at least 2.5 ...
openaire +1 more source
CADTH recommends that Sogroya should be reimbursed by public drug plans for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency [GHD]) if certain conditions are met. Sogroya should only be covered to treat children who are at least 2.5 ...
openaire +1 more source
Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency
Drugs of Today, 2022Growth hormone deficiency (GHD) is characterized by inadequate HG production from the anterior pituitary gland. Adult patients with GHD have increased fat mass, an abnormal lipid profile, decreased lean body mass and bone mineral density, decreased muscle strength and exercise endurance, and a diminished quality of life.
openaire +2 more sources
Growth Hormone & IGF Research, 2017
Somapacitan is an albumin-binding growth hormone derivative intended for once weekly administration, currently in clinical development for treatment of adult as well as juvenile GH deficiency. Nonclinical in vivo pharmacological characterisation of somapacitan was performed to support the clinical trials.
Peter, Thygesen +6 more
openaire +2 more sources
Somapacitan is an albumin-binding growth hormone derivative intended for once weekly administration, currently in clinical development for treatment of adult as well as juvenile GH deficiency. Nonclinical in vivo pharmacological characterisation of somapacitan was performed to support the clinical trials.
Peter, Thygesen +6 more
openaire +2 more sources
Growth Hormone & IGF Research
Somapacitan is the second generation of recombinant human growth hormone (rhGH) medication that retains the pharmacological effects of rhGH but exhibits a longer duration of action due to its reversible albumin-binding in the body. In general, the use of all recombinant growth hormone (rGH) analogues is banned by the human and animal sports regulatory ...
Yoshibumi, Shimizu +9 more
openaire +2 more sources
Somapacitan is the second generation of recombinant human growth hormone (rhGH) medication that retains the pharmacological effects of rhGH but exhibits a longer duration of action due to its reversible albumin-binding in the body. In general, the use of all recombinant growth hormone (rGH) analogues is banned by the human and animal sports regulatory ...
Yoshibumi, Shimizu +9 more
openaire +2 more sources
Effects of somapacitan on glucose metabolism in adults with GH deficiency
Endocrine Abstracts, 2022Gudmundur Johannsson +8 more
openaire +1 more source
The Journal of Clinical Endocrinology & Metabolism
Abstract Context Once-weekly somapacitan is approved for treating adults with growth hormone deficiency. Phase 3 trials support its noninferiority to daily growth hormone (GH); however, its effect on comprehensive metabolic outcome, including muscle strength, during routine care, remains ...
Yuka Oi-Yo +11 more
openaire +1 more source
Abstract Context Once-weekly somapacitan is approved for treating adults with growth hormone deficiency. Phase 3 trials support its noninferiority to daily growth hormone (GH); however, its effect on comprehensive metabolic outcome, including muscle strength, during routine care, remains ...
Yuka Oi-Yo +11 more
openaire +1 more source
Rare adverse event of treatment with somapacitan after switch from somatotropine
Endocrine Abstracts, 2023Matej Rakusa +2 more
openaire +1 more source